Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) shares saw unusually-high trading volume on Monday . Approximately 759,663 shares traded hands during trading, an increase of 73% from the previous session’s volume of 440,356 shares.The stock last traded at $1.25 and had previously closed at $1.16.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $5.00 price objective (down previously from $6.00) on shares of Eyegate Pharmaceuticals in a research note on Wednesday, November 15th.

The company has a debt-to-equity ratio of 0.01, a current ratio of 0.81 and a quick ratio of 0.81.

A hedge fund recently raised its stake in Eyegate Pharmaceuticals stock. Vanguard Group Inc. increased its holdings in shares of Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) by 0.8% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 247,319 shares of the specialty pharmaceutical company’s stock after buying an additional 1,988 shares during the period. Vanguard Group Inc. owned about 2.27% of Eyegate Pharmaceuticals worth $339,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 11.94% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This piece was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece on another domain, it was stolen and reposted in violation of international trademark & copyright laws. The correct version of this piece can be viewed at https://www.thecerbatgem.com/2017/12/11/eyegate-pharmaceuticals-eyeg-sees-large-volume-increase.html.

Eyegate Pharmaceuticals Company Profile

Eyegate Pharmaceuticals, Inc is a clinical-stage specialty pharmaceutical company. The Company is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. The Company’s lead product, EGP-437, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, which is delivered into the ocular tissues through its drug delivery system, the EyeGate II Delivery System.

Receive News & Stock Ratings for Eyegate Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyegate Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.